# Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas

> **NCT00035022** · PHASE1,PHASE2 · COMPLETED · sponsor: **BioCryst Pharmaceuticals** · enrollment: 71 (—)

## Conditions studied

- Leukemia, Lymphocytic
- Lymphoma

## Interventions

- **DRUG:** BCX-1777

## Key facts

- **NCT ID:** NCT00035022
- **Lead sponsor:** BioCryst Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** —
- **Final completion:** 2004-03
- **Target enrollment:** 71 (—)
- **Last updated:** 2006-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00035022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00035022, "Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00035022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*